Amlip

📦 Every order is covered by our Πολιτική Εγγύησης Επαναποστολής — if your parcel does not arrive within 20 business days, we reship it.

Why order from MedsBase

Our generic medications are sourced from WHO-GMP certified manufacturers and shipped worldwide in discreet, plain packaging — no medication name on the parcel exterior. Card payments are routed through a regulated processor (statement descriptors include a regulated card-payment processor — never “MedsBase” or any medication name). Crypto and SEPA bank transfer are also accepted. Every order is backed by our Reshipment Assurance Policy.

What Is Amlip?

Amlip is an oral 2.5 / 5 mg amlodipine tablet from Cipla, supplied in 30-180 tablets. Introduced 1990 (Pfizer as Norvasc / Istin). The reference DHP for hypertension worldwide.

Amlodipine belongs to the dihydropyridine calcium-channel blocker subclass, distinguished from the non-dihydropyridines (diltiazem, verapamil) by its selective action on vascular smooth muscle with minimal direct cardiac effect. This selectivity profile is clinically important: DHPs can be combined safely with beta-blockers (the combination is standard in angina), while non-DHPs cannot (additive bradycardia/heart-block risk).

How Amlodipine Works

Calcium-channel blockers bind L-type voltage-gated calcium channels and reduce calcium influx into the cell during depolarisation. In arterial smooth muscle, reduced calcium entry means less actin-myosin interaction and direct arterial vasodilation — lowering systemic vascular resistance and blood pressure.

Dihydropyridines are ~10-fold more potent on vascular smooth muscle than on cardiac muscle — so the dominant clinical effect is vasodilation, with minimal direct suppression of cardiac contractility or conduction. The body’s baroreflex can trigger mild reflex tachycardia after fast-onset vasodilation; amlodipine’s very long onset eliminates this effect clinically.

Onset of clinical effect: gradual onset over 6-12 hours, full effect at 7-8 days.

Approved and Evidence-Based Uses

• Uncomplicated hypertension — often first-line, particularly for Black patients and those over 55 (NICE, AHA)
• Hypertension + stable angina (dual indication)
• Prinzmetal / vasospastic angina — first-line
• Raynaud’s phenomenon
• Hypertension in heart failure with preserved ejection fraction (HF-pEF) — safer than non-DHP CCBs which are contraindicated in HF-REF
• Hypertension in pregnancy — not first-line but reasonable second option after methyldopa / labetalol / nifedipine MR

Pivotal trial evidence: ASCOT-BPLA (2005) — perindopril + amlodipine beat atenolol + thiazide for CV outcomes in hypertension, establishing the modern preference for CCB + ACEi/ARB over beta-blocker + thiazide. VALUE (2004) — amlodipine-based therapy had slight advantage over valsartan-based therapy on stroke+MI endpoints, driven largely by faster BP drop. ALLHAT (2002) — amlodipine equivalent to chlorthalidone for most outcomes, better than lisinopril for stroke in black patients.

Amlip Dosage

Hypertension:

• Starting dose: 5 mg once daily (2.5 mg if elderly, small body size, or hepatic impairment)
• Target dose: 5-10 mg once daily
• Maximum: 10 mg once daily
• Titrate every 1-2 weeks based on BP response and tolerability (particularly oedema)

Angina: 5-10 mg once daily for chronic stable and vasospastic angina

Administration: once daily (or twice daily for IR nifedipine formulations). Swallow whole — do NOT crush or split extended-release formulations (delivers an IR dose with risk of hypotension). Take with or without food.

Discontinuation: no specific withdrawal syndrome; can be stopped without taper. BP will return to pre-treatment levels within 1-2 weeks.

Side Effects

Common (>5%, mostly mild and transient):

• Peripheral (ankle) oedema — Peripheral (ankle) oedema from pre-capillary vasodilation — dose-related (up to 25% at 10 mg/day). Not from fluid overload; does not respond to diuretics. Management: reduce dose, combine with an ACE inhibitor or ARB (which neutralise the oedema via balanced pre-and-post-capillary vasodilation), or switch to a non-DHP CCB (diltiazem, verapamil) if the heart-rate effect is acceptable.
• Flushing (warm face and upper body)
• Headache (particularly at start of therapy; usually adapts within 2-4 weeks)
• Minor palpitations (less common than with short-acting nifedipine)
• Dizziness, postural hypotension
• Fatigue
• Mild constipation (less than non-DHPs)

Uncommon:

• Rash, pruritus
• Nausea, abdominal discomfort
• Erectile dysfunction (rare)
• Liver enzyme elevations (usually mild, reversible)
• Rare reports of photosensitivity

Contraindications & Cautions

• Known hypersensitivity to amlodipine or dihydropyridine class
• Cardiogenic shock
• Severe aortic stenosis (can cause critical hypotension)
• Unstable angina or MI within 1 month (DHPs other than amlodipine)
• Obstructive hypertrophic cardiomyopathy (reduces outflow gradient dynamically)
• Severe hepatic impairment (all DHPs are hepatically metabolised)

Pregnancy: amlodipine is not first-line in pregnancy but has reassuring observational data; a reasonable second-line choice if labetalol, methyldopa, and nifedipine MR are ineffective or contraindicated.

Breastfeeding: small amounts in breast milk; generally considered acceptable with infant monitoring.

Drug Interactions

• Grapefruit juice — inhibits CYP3A4 metabolism; can raise plasma levels of amlodipine and particularly nifedipine/nimodipine by 2-3×. Avoid on treatment days, or use consistently if at all.
• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, cobicistat) — raise CCB plasma levels; reduce dose or avoid
• Strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, St John’s wort) — reduce CCB plasma levels; may need dose increase
• Simvastatin — amlodipine modestly increases simvastatin exposure; cap simvastatin at 20 mg/day when combined
• Beta-blockers — DHPs combine safely with beta-blockers (the combination is standard in angina — beta-blocker blunts reflex tachycardia, CCB provides vasodilation). Distinct from non-DHP CCBs (diltiazem, verapamil) which should NOT be combined with beta-blockers.
• Other antihypertensives — generally complementary; monitor BP
• Sildenafil / tadalafil (PDE5 inhibitors for erectile dysfunction) — additive hypotension; caution particularly at high CCB doses

Calcium-Channel Blocker Class at a Glance

DHP vs non-DHP — why it matters: DHPs (amlodipine, nifedipine) act selectively on arterial smooth muscle with minimal cardiac effect — safe to combine with beta-blockers. Non-DHPs (diltiazem, verapamil) slow AV nodal conduction and reduce cardiac contractility — do NOT combine with beta-blockers (additive bradycardia, heart block, acute heart failure risk). If your patient is already on a beta-blocker, use a DHP.

Storage

Store Amlip below 25°C. Protect from light. Keep out of reach of children.

Frequently Asked Questions

Why have my ankles started swelling after Amlip?

Peripheral oedema is a class effect of dihydropyridines, caused by pre-capillary arteriolar dilation that raises hydrostatic pressure in the lower-leg venules. It is NOT fluid overload and does NOT respond to diuretics. Management options: (1) reduce the CCB dose; (2) add an ACE inhibitor or ARB which balances pre- and post-capillary vasodilation and eliminates the oedema mechanism (often the preferred solution); (3) switch to a non-DHP CCB (diltiazem, verapamil) if rate-related side effects are acceptable; (4) leg elevation and compression stockings as adjuncts.

How long does Amlip take to lower blood pressure?

Gradual onset — measurable BP reduction within 24-48 hours; full effect at 7-8 days. Amlodipine’s extremely long half-life (35-50 h) gives one of the smoothest BP profiles in cardiovascular medicine.

Can I take Amlip with a beta-blocker?

Yes — DHPs combine safely with beta-blockers. The combination is standard in angina: the DHP vasodilates and reduces myocardial oxygen demand; the beta-blocker blunts the reflex tachycardia. This is different from non-DHP CCBs (diltiazem, verapamil) which should NOT be combined with beta-blockers due to additive bradycardia and heart-block risk.

Can I eat grapefruit on Amlip?

Grapefruit (juice and fresh fruit) inhibits CYP3A4 metabolism and can raise amlodipine plasma levels by 2-3×, increasing the risk of hypotension, dizziness, and oedema. Best practice: avoid grapefruit/juice while on CCBs, or consume consistently (your dose is titrated to BP response; sporadic grapefruit disrupts that).

Is Amlip safe in pregnancy?

Amlodipine is not first-line in pregnancy but has reassuring observational data; a reasonable second-line if labetalol, methyldopa, and nifedipine MR are ineffective or contraindicated. Discuss with your obstetrician.

Can I combine Amlip with my other BP medications?

Yes — DHP CCBs combine well with ACE inhibitors (ramipril, lisinopril), ARBs (losartan, telmisartan, olmesartan), beta-blockers (bisoprolol, metoprolol), and thiazide diuretics (HCTZ). The ACEi/ARB + CCB combination is particularly useful because it eliminates the ankle oedema side effect.

Where can I buy Amlip online?

You can buy Amlip (amlodipine 2.5 / 5 mg, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.

Related Antihypertensives on MedsBase

• Aquazide — Hydrochlorothiazide diuretic
• Cardipin Retard — Nifedipine 20 mg ER
• Depin — Nifedipine 5/10 mg
• Losar — Losartan (ARB alternative)
• Nicardia Retard — Nifedipine retard 10/20/30 mg
• Nimodip — Nimodipine (subarachnoid haemorrhage)
• Browse all High Blood Pressure Medications

Related Alternatives

Other products in Χρόνιες Παθήσεις that customers also view:

• Etoford
• Hivus LR
• Fluvoxin
• Q-Siz SR 400
• Celkeran

More options in High Blood Pressure Medication

Ranked by recent MedsBase order volume — what other customers in this category are picking.

Telmaheal

US$9.00 – US$36.00Gama de preços: US$9.00 a US$36.00

Losar

US$6.53 – US$29.25Gama de preços: US$6.53 a US$29.25

Amlode

US$5.50 – US$24.00Gama de preços: US$5.50 a US$24.00

Minoxytop

US$22.00 – US$170.00Gama de preços: US$22.00 a US$170.00